Jaime Yoke May Chan, Farida Islahudin, Mohd Makmor-Bakry, Nurul Ain Mohd Tahir, Clare Hui Hong Tan
{"title":"慢性肾病合并代谢性酸中毒患者口服碳酸氢钠的接受和依从性：一项多中心横断面调查","authors":"Jaime Yoke May Chan, Farida Islahudin, Mohd Makmor-Bakry, Nurul Ain Mohd Tahir, Clare Hui Hong Tan","doi":"10.21315/mjms-09-2024-693","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Oral sodium bicarbonate is recommended for treating metabolic acidosis in chronic kidney disease (CKD). However, limited information exists on patient preferences between sodium bicarbonate tablets and powdered solutions. This study aimed to provide baseline data regarding the acceptance and adherence of patients with CKD to oral sodium bicarbonate therapy.</p><p><strong>Methods: </strong>This prospective multicentre cross-sectional study was conducted across five Malaysian government hospitals involving adult patients with pre-dialysis CKD. A questionnaire assessed demographics, clinical characteristics, bicarbonate treatment, and included the Medication Acceptance Questionnaire (MAQ) (convenience, taste, appearance, efficacy, and tolerability), along with an individual adherence assessment.</p><p><strong>Results: </strong>Among 203 patients analysed, the median age was 60 years (interquartile range [IQR], 16 years), and the majority were at stage 5 (<i>n</i> = 138, 68.0%). Sodium bicarbonate acceptance scores above 70% for all MAQ domains were significantly higher among tablet users than those of the powdered solution users, who only had scores above 70% for convenience, taste and tolerability domains. Tablet users were more adherent to treatment (88.9% vs. 70.9%, <i>p</i> < 0.014). A positive correlation was found between self-reported adherence and all five MAQ domain scores for the oral powdered sodium bicarbonate solution (convenience: <i>r</i> <i><sub>s</sub></i> = 0.223, <i>p</i> = 0.005; taste: <i>r</i> <i><sub>s</sub></i> = 0.223, <i>p</i> = 0.005; appearance: <i>r</i> <i><sub>s</sub></i> = 0.161, <i>p</i> = 0.043; efficacy: <i>r</i> <i><sub>s</sub></i> = 0.247, <i>p</i> = 0.002; tolerability: <i>r</i> <i><sub>s</sub></i> = 0.279, <i>p</i> < 0.001). For tablet users, significant positive correlations were observed between self-reported adherence and the convenience (<i>r</i> <i><sub>s</sub></i> = 0.413, <i>p</i> = 0.005), appearance (<i>r</i> <i><sub>s</sub></i> = 0.449, <i>p</i> = 0.002), and efficacy (<i>r</i> <i><sub>s</sub></i> = 0.355, <i>p</i> = 0.017) domains.</p><p><strong>Conclusion: </strong>Tablet formulation of sodium bicarbonate was associated with higher patient acceptance and adherence, potentially leading to improved long-term clinical outcomes.</p>","PeriodicalId":47388,"journal":{"name":"Malaysian Journal of Medical Sciences","volume":"32 1","pages":"88-98"},"PeriodicalIF":1.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097153/pdf/","citationCount":"0","resultStr":"{\"title\":\"Exploration of Oral Sodium Bicarbonate Acceptance and Adherence among Chronic Kidney Disease Patients with Metabolic Acidosis: A Multicentre Cross-Sectional Survey.\",\"authors\":\"Jaime Yoke May Chan, Farida Islahudin, Mohd Makmor-Bakry, Nurul Ain Mohd Tahir, Clare Hui Hong Tan\",\"doi\":\"10.21315/mjms-09-2024-693\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Oral sodium bicarbonate is recommended for treating metabolic acidosis in chronic kidney disease (CKD). However, limited information exists on patient preferences between sodium bicarbonate tablets and powdered solutions. This study aimed to provide baseline data regarding the acceptance and adherence of patients with CKD to oral sodium bicarbonate therapy.</p><p><strong>Methods: </strong>This prospective multicentre cross-sectional study was conducted across five Malaysian government hospitals involving adult patients with pre-dialysis CKD. A questionnaire assessed demographics, clinical characteristics, bicarbonate treatment, and included the Medication Acceptance Questionnaire (MAQ) (convenience, taste, appearance, efficacy, and tolerability), along with an individual adherence assessment.</p><p><strong>Results: </strong>Among 203 patients analysed, the median age was 60 years (interquartile range [IQR], 16 years), and the majority were at stage 5 (<i>n</i> = 138, 68.0%). Sodium bicarbonate acceptance scores above 70% for all MAQ domains were significantly higher among tablet users than those of the powdered solution users, who only had scores above 70% for convenience, taste and tolerability domains. Tablet users were more adherent to treatment (88.9% vs. 70.9%, <i>p</i> < 0.014). A positive correlation was found between self-reported adherence and all five MAQ domain scores for the oral powdered sodium bicarbonate solution (convenience: <i>r</i> <i><sub>s</sub></i> = 0.223, <i>p</i> = 0.005; taste: <i>r</i> <i><sub>s</sub></i> = 0.223, <i>p</i> = 0.005; appearance: <i>r</i> <i><sub>s</sub></i> = 0.161, <i>p</i> = 0.043; efficacy: <i>r</i> <i><sub>s</sub></i> = 0.247, <i>p</i> = 0.002; tolerability: <i>r</i> <i><sub>s</sub></i> = 0.279, <i>p</i> < 0.001). For tablet users, significant positive correlations were observed between self-reported adherence and the convenience (<i>r</i> <i><sub>s</sub></i> = 0.413, <i>p</i> = 0.005), appearance (<i>r</i> <i><sub>s</sub></i> = 0.449, <i>p</i> = 0.002), and efficacy (<i>r</i> <i><sub>s</sub></i> = 0.355, <i>p</i> = 0.017) domains.</p><p><strong>Conclusion: </strong>Tablet formulation of sodium bicarbonate was associated with higher patient acceptance and adherence, potentially leading to improved long-term clinical outcomes.</p>\",\"PeriodicalId\":47388,\"journal\":{\"name\":\"Malaysian Journal of Medical Sciences\",\"volume\":\"32 1\",\"pages\":\"88-98\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097153/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Malaysian Journal of Medical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21315/mjms-09-2024-693\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Malaysian Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21315/mjms-09-2024-693","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
背景：口服碳酸氢钠被推荐用于治疗慢性肾脏疾病（CKD）代谢性酸中毒。然而，关于患者对碳酸氢钠片剂和粉状溶液的偏好的信息有限。本研究旨在提供CKD患者接受和坚持口服碳酸氢钠治疗的基线数据。方法：这项前瞻性多中心横断面研究在马来西亚五家政府医院进行，涉及透析前CKD的成年患者。问卷评估了人口统计学、临床特征、碳酸氢盐治疗，包括药物接受度问卷（MAQ）（便利性、味道、外观、疗效和耐受性），以及个人依从性评估。结果：203例患者中位年龄为60岁（四分位数间距[IQR]， 16岁），以5期患者居多（n = 138, 68.0%）。片剂使用者对碳酸氢钠所有MAQ域的接受度得分均高于70%，而粉状溶液使用者仅在方便度、味道和耐受性域得分高于70%。服药者对治疗的依从性更高（88.9% vs. 70.9%, p < 0.014）。自我报告的依从性与口服粉状碳酸氢钠溶液的所有5个MAQ域评分呈正相关(方便性：r s = 0.223, p = 0.005；口感：r s = 0.223, p = 0.005；外观：r s = 0.161, p = 0.043；疗效：r s = 0.247, p = 0.002；耐受性：r s = 0.279, p < 0.001)。对于片剂使用者，自我报告的依从性与便利性（r s = 0.413, p = 0.005）、外观（r s = 0.449, p = 0.002）和疗效（r s = 0.355, p = 0.017）领域呈显著正相关。结论：碳酸氢钠片剂配方与更高的患者接受度和依从性相关，可能导致改善的长期临床结果。
Exploration of Oral Sodium Bicarbonate Acceptance and Adherence among Chronic Kidney Disease Patients with Metabolic Acidosis: A Multicentre Cross-Sectional Survey.
Background: Oral sodium bicarbonate is recommended for treating metabolic acidosis in chronic kidney disease (CKD). However, limited information exists on patient preferences between sodium bicarbonate tablets and powdered solutions. This study aimed to provide baseline data regarding the acceptance and adherence of patients with CKD to oral sodium bicarbonate therapy.
Methods: This prospective multicentre cross-sectional study was conducted across five Malaysian government hospitals involving adult patients with pre-dialysis CKD. A questionnaire assessed demographics, clinical characteristics, bicarbonate treatment, and included the Medication Acceptance Questionnaire (MAQ) (convenience, taste, appearance, efficacy, and tolerability), along with an individual adherence assessment.
Results: Among 203 patients analysed, the median age was 60 years (interquartile range [IQR], 16 years), and the majority were at stage 5 (n = 138, 68.0%). Sodium bicarbonate acceptance scores above 70% for all MAQ domains were significantly higher among tablet users than those of the powdered solution users, who only had scores above 70% for convenience, taste and tolerability domains. Tablet users were more adherent to treatment (88.9% vs. 70.9%, p < 0.014). A positive correlation was found between self-reported adherence and all five MAQ domain scores for the oral powdered sodium bicarbonate solution (convenience: rs = 0.223, p = 0.005; taste: rs = 0.223, p = 0.005; appearance: rs = 0.161, p = 0.043; efficacy: rs = 0.247, p = 0.002; tolerability: rs = 0.279, p < 0.001). For tablet users, significant positive correlations were observed between self-reported adherence and the convenience (rs = 0.413, p = 0.005), appearance (rs = 0.449, p = 0.002), and efficacy (rs = 0.355, p = 0.017) domains.
Conclusion: Tablet formulation of sodium bicarbonate was associated with higher patient acceptance and adherence, potentially leading to improved long-term clinical outcomes.
期刊介绍：
The Malaysian Journal of Medical Sciences (MJMS) is a peer-reviewed, open-access, fully online journal that is published at least six times a year. The journal’s scope encompasses all aspects of medical sciences including biomedical, allied health, clinical and social sciences. We accept high quality papers from basic to translational research especially from low & middle income countries, as classified by the United Nations & World Bank (https://datahelpdesk.worldbank.org/knowledgebase/ articles/906519), with the aim that published research will benefit back the bottom billion population from these countries. Manuscripts submitted from developed or high income countries to MJMS must contain data and information that will benefit the socio-health and bio-medical sciences of these low and middle income countries. The MJMS editorial board consists of internationally regarded clinicians and scientists from low and middle income countries.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
